拉丁美洲药物性肝损伤:拉丁美洲DILI(LATINDILI)网络10年经验
LATINDILI网络前瞻性纳入468例特发性药物性肝损伤病例,女性占62%,平均年龄49岁,肝细胞损伤型为主(62%),黄疸占60%,住院率42%,致命结局4.1%,24例(12%)发展为慢性DILI。最常见药物类别为全身抗感染药(31%)、肌肉骨骼系统药物(12%)、抗肿瘤和免疫调节剂(11%)及草药和膳食补充剂(9%)。抗结核药、尼美舒利和草药膳食补充剂与最差结局相关。
要点
- 拉丁美洲DILI以肝细胞损伤型为主(62%),黄疸占60%,住院率42%,致命结局4.1%。
- 最常见药物类别为全身抗感染药(31%),草药和膳食补充剂占9%且死亡率高。
- Hy's law预测价值因药物而异:抗结核药、尼美舒利和草药膳食补充剂结局最差。
核心结论
- 拉丁美洲DILI特征与其他前瞻性注册研究相当,但致病药物模式不同,草药和膳食补充剂发病率增加且死亡率高,尼美舒利和呋喃妥因亦如此。
- 公共卫生政策应提高对这些化合物潜在不良反应的认识。
研究设计与样本
- LATINDILI网络前瞻性招募的DILI病例分析,共纳入468例特发性DILI病例。
- 收集人口学、临床表现、组织学发现和结局,可疑药物按解剖治疗化学分类,因果关系采用RUCAM量表评估。
主要发现
- 468例中女性占62%,平均年龄49岁;肝细胞损伤型占62%,黄疸占60%,住院率42%。
- 致命结局占4.1%,24例(12%)发展为慢性DILI。
- 最常见药物类别为全身抗感染药(31%)、肌肉骨骼系统药物(12%)、抗肿瘤和免疫调节剂(11%)、草药和膳食补充剂(9%)。
- 由抗菌药或免疫抑制剂所致DILI患者均无致命结局。
- Hy's law显示药物特异性预测价值:抗结核药、尼美舒利和草药膳食补充剂与最差结局相关,而阿莫西林-克拉维酸、呋喃妥因和双氯芬酸所致且符合Hy's law的DILI无致命结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Latin America is a region of great interest for studying the clinical presentation of idiosyncratic drug-induced liver injury (DILI). A comprehensive analysis of patients enrolled into the LATINDILI Network over a decade is presented. METHODS: Demographics, clinical presentation, histological findings and outcome of prospectively recruited DILI cases in the LATINDILI Network were analyzed. Suspected culprit drugs were classified according to the Anatomical Therapeutic Chemical classification. Causality was assessed using the Roussel Uclaf Causality Assessment Method (RUCAM) scale. RESULTS: Overall, 468 idiosyncratic DILI cases were analyzed (62% women; mean age, 49 years). Hepatocellular injury predominated (62%); jaundice was present in 60% of patients, and 42% were hospitalized. Of the cases, 4.1% had a fatal outcome, and 24 patients (12%) developed chronic DILI. The most common drug classes were systemic anti-infectives (31%), musculoskeletal agents (12%), antineoplastic and immunomodulating agents (11%), and herbal and dietary supplements (9%). Notably, none of the patients with DILI due to antibacterials or immunosuppressants had a fatal outcome. In fact, Hy's law showed to have drug-specific predictive value, with anti-tuberculosis drugs, nimesulide, and herbal and dietary supplements associated with the worst outcome, whereas DILI caused by amoxicillin-clavulanate, nitrofurantoin, and diclofenac, which fulfilled Hy's law, did not have a fatal outcome. CONCLUSION: Features of DILI in Latin America are comparable to other prospective registries. However, the pattern of drugs responsible for DILI differs. An increasing incidence of herbal and dietary supplements, with high mortality rate, and likewise, nimesulide and nitrofurantoin, was noted. Thus, public health policies should raise awareness of the potential adverse effects of these compounds.
引用
- Bessone F, Hernandez N, Medina-Caliz I, et al. Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network. Clin Gastroenterol Hepatol. 2024. PMID: 38992407. doi:10.1016/j.cgh.2024.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。